Drug intelligence / Profile preview

CM9241GRU

Development stage: Unknown
Lead developer: Ache Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CM9241GRU is an investigational antiallergic drug being developed by Aché Laboratórios Farmacêuticos for the treatment of perennial allergic rhinitis. It is a new molecular entity currently in phase 3 clinical trials, with its mechanism of action not yet defined or publicly disclosed. The drug is administered as a tablet and aims to relieve nasal symptoms associated with non-seasonal allergen exposure in adults diagnosed with perennial allergic rhinitis[1][2][4].

Beyond the preview

Go deeper on CM9241GRU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM9241GRU.

Explore the full profile